You just read:

CutisPharma Announces FDA Approval Of FIRVANQ™ For Treatment Of Clostridium Difficile Associated Diarrhea (CDAD) And Staphylococcus Aureus Colitis

News provided by

CutisPharma, Inc.

Jan 29, 2018, 08:00 ET